NewsRx

Search our medical news database

Severe Combined Immunodeficiency Disease

T-Cell Directed Therapy Improves Immunological Function

Published in Gene Therapy Weekly, October 11th, 1999

T-cell directed gene therapy in a boy with adenosine daminase (ADA)-severe combined immunodeficiency disease (SCID) resulted in improved immunological function.

N. Kawamura and colleagues from Hokkaido University, Japan, issued a case report on gene therapy for ADA. Their data were published in the Journal of Immunology ("In vivo Kinetics of Transduced Cells in Peripheral T-Cell-Directed Gene Therapy: Role of CD8+ Cells in Improved Immunological Function in an Adenosine Deaminase (ADA)-SCID Patient," Journal of Immunology, August 15, 1999;163(4):2256-2261).

"We previously reported successful peripheral T-cell-directed gene therapy in a...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook